Behavior of the Genetic Markers at Screening During the First Trimester of Pregnancy in Euploid Fetuses

Overview

Journal Rev Bras Ginecol Obstet

Specialty Gynecology & Obstetrics

Date 2022 Jun 6

PMID 35667377

Authors

Ximena Carolina Romero Infante

Montserrat Uriel

Alejandra Gutierrez

Maria Fernanda Hernandez

Andres Felipe Hernandez

Laura Catalina Jimenez

Jeadran Nevardo Malagon-Rojas

Sara Rincon Franco

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to describe the behavior of chromosomopathy screenings in euploid fetuses.

Methods: This is a prospective descriptive study with 566 patients at 11 to 14 weeks of gestation. The associations between ultrasound scans and serological variables were studied. For the quantitative variables we used the Spearman test; for the qualitative with quantitative variables the of Mann-Whitney U-test; and for qualitative variables, the X test was applied. Significance was set at ≤ 0.05.

Results: We have found that gestational age has correlation with ductus venosus, nuchal translucency, free fraction of β subunit of human chorionic gonadotropin, pregnancy-associated plasma protein-A and placental growth factor; there is also a correlation between history of miscarriages and nasal bone. Furthermore, we correlated body mass index with nuchal translucency, free fraction of β subunit of human chorionic gonadotropin, and pregnancy-associated plasma protein-A. Maternal age was associated with free fraction of β subunit of human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Conclusion: Our study demonstrates for the first time the behavior of the biochemical and ultrasonographic markers of chromosomopathy screenings during the first trimester in euploid fetuses in Colombia. Our information is consistent with international reference values. Moreover, we have shown the correlation of different variables with maternal characteristics to determine the variables that could help with development of a screening process during the first trimester with high detection rates.

Citing Articles

The Relationship Between Thrombophilia and Modifications in First-Trimester Prenatal Screening Markers.

Murvai V, Radu C, Galis R, Ghitea T, Tataru-Copos A, Vesa A Medicina (Kaunas). 2025; 61(2).

PMID: 40005435 PMC: 11857445. DOI: 10.3390/medicina61020318.

References

Florjanski J, Fuchs T, Zimmer M, Homola W, Pomorski M, Blok D . The role of ductus venosus Doppler flow in the diagnosis of chromosomal abnormalities during the first trimester of pregnancy. Adv Clin Exp Med. 2013; 22(3):395-401. View

Zaragoza E, Akolekar R, Poon L, Pepes S, Nicolaides K . Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol. 2009; 33(4):382-6. DOI: 10.1002/uog.6331. View

Cuckle H, Spencer K, Nicolaides K . Down syndrome screening marker levels in women with a previous aneuploidy pregnancy. Prenat Diagn. 2005; 25(1):47-50. DOI: 10.1002/pd.1082. View

Maiz N, Valencia C, Kagan K, Wright D, Nicolaides K . Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009; 33(5):512-7. DOI: 10.1002/uog.6330. View

Veduta A, Vayna A, Duta S, Panaitescu A, Popescu F, Bari M . The first trimester combined test for aneuploidies - a single center experience. J Matern Fetal Neonatal Med. 2017; 31(16):2091-2096. DOI: 10.1080/14767058.2017.1336220. View

Matias A, Gomes C, Flack N, Montenegro N, Nicolaides K . Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol. 1999; 12(6):380-4. DOI: 10.1046/j.1469-0705.1998.12060380.x. View

Kasdaglis T, Aberdeen G, Turan O, Kopelman J, Atlas R, Jenkins C . Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies. Ultrasound Obstet Gynecol. 2010; 35(3):280-5. DOI: 10.1002/uog.7548. View

Khambalia A, Roberts C, Morris J, Tasevski V, Nassar N . Maternal body weight and first trimester screening for chromosomal anomalies. Aust N Z J Obstet Gynaecol. 2014; 54(5):490-2. DOI: 10.1111/ajo.12231. View

Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides K . Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn. 2003; 23(4):306-10. DOI: 10.1002/pd.588. View

10.

Jou H, Wu S, Li T, Hsu H, Tzeng C, Hsieh F . Relationship between fetal nuchal translucency and crown-rump length in an Asian population. Ultrasound Obstet Gynecol. 2001; 17(2):111-4. DOI: 10.1046/j.1469-0705.2001.00332.x. View

11.

Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides K . First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther. 2013; 35(2):118-26. DOI: 10.1159/000357430. View

12.

Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides K . Maternal serum IGF-I, IGFBP-1 and IGFBP-3 at 11-13 weeks in trisomy 21 and trisomy 18 pregnancies. Eur J Obstet Gynecol Reprod Biol. 2011; 157(2):166-8. DOI: 10.1016/j.ejogrb.2011.03.029. View

13.

Yu B, Lu B, Zhang B, Zhang X, Chen Y, Zhou Q . Overall evaluation of the clinical value of prenatal screening for fetal-free DNA in maternal blood. Medicine (Baltimore). 2017; 96(27):e7114. PMC: 5502138. DOI: 10.1097/MD.0000000000007114. View

14.

Nicolaides K . Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004; 191(1):45-67. DOI: 10.1016/j.ajog.2004.03.090. View

15.

Nicolaides K . Turning the pyramid of prenatal care. Fetal Diagn Ther. 2011; 29(3):183-96. DOI: 10.1159/000324320. View

16.

Kalayci H, Yilmaz Baran S, Dogan Durdag G, Yetkinel S, Alemdaroglu S, Ozdogan S . Reference values of the pulsatility index for pregnant women between 11 and 13 weeks of gestation. J Matern Fetal Neonatal Med. 2018; 33(7):1134-1139. DOI: 10.1080/14767058.2018.1517152. View

17.

Zoppi M, Ibba R, Axiana C, Floris M, Manca F, Monni G . Absence of fetal nasal bone and aneuploidies at first-trimester nuchal translucency screening in unselected pregnancies. Prenat Diagn. 2003; 23(6):496-500. DOI: 10.1002/pd.628. View

18.

Diaz V, Guevara R, Brito J . [Nuchal translucency and ductus venosus as ultrasound markers of chromosomal abnormalities]. Invest Clin. 2009; 49(4):523-32. View

19.

Sorensen S, Momsen G, Sundberg K, Friis-Hansen L, Jorgensen F . First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software. Clin Chem. 2011; 57(7):1023-31. DOI: 10.1373/clinchem.2010.161299. View

20.

Kagan K, Wright D, Nicolaides K . First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2014; 45(1):42-7. DOI: 10.1002/uog.14691. View